Antibody and T-Cell Immunotherapy for boosting patient body’s defenses to treat Cancer.

Our mission is to develop Immunotherapeutic agents for treatment of human cancer.

opn blockade immunotherapy

Despite the breakthrough of cancer immunotherapy with durable efficacy in many types of human cancers, colorectal and pancreatic cancers do not respond to current immuntherapy. There are therefore an unmet need and hugh market for new immunotherapuetic agents for colorectal and pancreatic cancers.

Lipid nanoparticle dna immunotherapy

Lung metastases occurs in approximately 30% of cancer patients with a metastatic disease and is the 2nd most common metastases in human cancer patients. ChemMedImmune Inc. is developing IFNA2-LNP01, a cationic lipid nanoparticle-encapsulated IFNα2-encoding mini-plasmid DNA for treatment of patients with lung metastases.

Epigenetic dual targeting of tumor and t cells

Despite the breakthrough of immune checkpoint inhibitor (ICI) immunotherapy in treatment of human cancer. Human colorectal cancer stands out as one of the few human cancers that do not respond to ICI immunotherapy. In human colorectal cancer, only the microsatellite instable (MSI-H) subtype, which accounts for only 10-15% of all human colorectal cancer cases, responds to PD-(L)1-based ICI immunotherapy.